Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

Toronto, Ontario – June 3, 2026 – TheNewswire –  NeuroThera Labs Inc. (TSXV: NTLX) (the “ Company ” or “ NeuroThera ”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed its previously announced acquisition (the “ Transaction ”) of an aggregate of 56,375 ordinary shares (the “ Purchased Shares ”) in the capital of CliniQuantum Ltd. (“ CliniQuantum ”), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum, pursuant to a share purchase agreement dated March 9, 2026, as amended by an amending agreement dated April 30, 2026 (collectively, the “ SPA ”), among the Company, CliniQuantum and the holders of the Purchased Shares (collectively, the “ Selling Shareholders ”). The Transaction was initially announced by news release dated March 10, 2026 and updated by news release dated May 27, 2026.   As consideration for the Purchased Shares, the Company issued an aggregate of 56,600,000 common shares in the capital of the Company (the “ Consideration Shares ”) from treasury to the Selling Shareholders, representing an aggregate deemed value of approximately $9,459,954.20 (the “ Purchase Price ”) based on the 20-day volume weighted average trading price of the Company's common shares (the “ Current Market Price ”) on the TSX Venture Exchange (the “ TSXV ”) as at the date of the SPA. No cash consideration was paid for the Purchased Shares.